drugset / Trial / NCT02340975
A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab, MEDI4736 monotherapy or tremelimumab monotherapy in participants with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma.
Timeline
- Start
- 2015-03-31
- Primary completion
- 2019-04-29
- Completion
- 2019-04-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 10 mg/kg | Intravenous |